Planetpharma

Planetpharma is a French pharmaceutical importer and wholesaler headquartered in Le Grand-Quevilly, Normandy, France. Established on February 1, 1992, the company operates under the legal form of a Société Anonyme (SA) with a Board of Directors. It specializes in the wholesale distribution of pharmaceutical products, serving as a critical link in the supply chain between manufacturers and healthcare providers. (entreprises.lagazettefrance.fr)

As a subsidiary of the UbiPharm group, Planetpharma plays a pivotal role in the pharmaceutical distribution network, particularly focusing on the import and export of pharmaceutical products. The company manages the distribution of medications for over 100 pharmaceutical laboratories to 150 wholesaler-distributor customers across 23 countries in Africa and France’s overseas departments and territories.

Planetpharma operates two storage platforms in France, covering a total area of 25,000 square meters with a combined storage capacity of 37,000 pallets. These facilities are equipped with automated systems that perform storage and preparation operations efficiently, ensuring compliance with good distribution practices. The strategic location of these warehouses near the ports of Rouen and Le Havre facilitates efficient logistics and distribution, both within France and to international markets.

In France's pharmaceutical supply chain, Planetpharma functions primarily as a wholesale distributor and pharmaceutical depot. It imports pharmaceutical products from various countries, including India, and distributes them to a network of customers, including wholesalers and healthcare providers. Additionally, Planetpharma is responsible for managing regulatory affairs, such as the registration and maintenance of marketing authorizations for drugs, ensuring compliance with French regulations.

Planetpharma's sourcing strategy exhibits a high degree of concentration, with the top five products accounting for 100% of its imports from India. This indicates a strategic focus on a limited range of products, potentially to leverage volume discounts and streamline operations. The significant import values of these products—Azithromycin ($2.5M), Cefixime ($2.3M), Ceftriaxone ($1.8M), Domperidone ($1.6M), and Ornidazole ($185K)—suggest a stable and ongoing relationship with Indian suppliers. The consistent import volumes over the years further reflect the stability and reliability of these supplier relationships.

Planetpharma's supply chain resilience is bolstered by its diversified supplier base, comprising 44 unique Indian suppliers. This diversification mitigates risks associated with dependency on a single supplier. The company's dual storage platforms, equipped with automated systems, enhance operational efficiency and continuity. However, the concentration of imports in a few key products may expose the company to risks related to market fluctuations or supply disruptions in these specific product categories.

Planetpharma's focused sourcing strategy positions it to negotiate favorable terms with suppliers, potentially securing better pricing and priority access to products. For Indian exporters, this presents an opportunity to strengthen relationships with Planetpharma by ensuring consistent product quality and reliable delivery schedules. Expanding the product range offered to Planetpharma could also open avenues for increased collaboration and market penetration.

In France, the primary regulatory authority overseeing pharmaceutical imports is the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM). Key legislation governing pharmaceutical imports includes the Public Health Code and the European Union's directives on medicinal products. The marketing authorization pathway for Indian generics involves obtaining a Marketing Authorization (MA) from the ANSM, which requires compliance with EU standards for quality, safety, and efficacy.

Import licensing requirements in France stipulate that pharmaceutical products must be authorized for sale within the EU. Good Manufacturing Practice (GMP) certificates recognized by the European Union, such as EU GMP, WHO GMP, or PIC/S, are mandatory for imported products. Additionally, wholesale distribution authorization is required, ensuring that distributors adhere to stringent standards for storage, handling, and distribution of pharmaceutical products.

Imported pharmaceutical products must undergo batch testing to verify their quality and compliance with regulatory standards. Stability requirements ensure that products maintain their efficacy and safety throughout their shelf life. Labeling must be in French, providing clear information on dosage, administration, and potential side effects. Serialization mandates are in place to enhance traceability and prevent counterfeit products from entering the market.

Between 2024 and 2026, France implemented several regulatory changes affecting pharmaceutical imports. These include stricter compliance requirements for GMP certifications, enhanced scrutiny of labeling and packaging to prevent counterfeit products, and updated procedures for obtaining Marketing Authorizations for foreign generics. These changes aim to bolster patient safety and ensure the quality of imported pharmaceutical products.

Planetpharma's focus on importing advanced antibiotics, general antibiotics, and gastrointestinal products aligns with the high demand for these medications in France. The substantial import values of Azithromycin, Cefixime, and Ceftriaxone indicate a strategic emphasis on these therapeutic areas, likely driven by their critical role in treating a wide range of infections and gastrointestinal disorders. This product strategy positions Planetpharma to meet the essential healthcare needs of the French population.

Planetpharma's sourcing strategy centers on generic drugs, primarily from India, leveraging the country's robust pharmaceutical manufacturing capabilities. The company's preference for finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, reflects a focus on ready-to-market products that meet EU regulatory standards. India's established reputation for producing high-quality generics makes it a strategic partner for Planetpharma's procurement needs.

Based on its product mix, Planetpharma serves multiple segments of the French pharmaceutical market, including retail pharmacies, hospitals, and wholesale distribution channels. The company's emphasis on essential antibiotics and gastrointestinal medications positions it as a key supplier to healthcare providers and distributors, ensuring the availability of critical treatments across various healthcare settings.

There is a realistic opportunity for new Indian suppliers to collaborate with Planetpharma, particularly in the therapeutic areas of advanced antibiotics and gastrointestinal products. Gaps in Planetpharma's current sourcing may exist in specialized formulations or emerging treatments, presenting avenues for Indian exporters to introduce innovative products. Establishing relationships with Planetpharma could lead to increased market access and distribution opportunities within France and its overseas territories.

Indian exporters aiming to supply Planetpharma and the French market must obtain GMP certifications recognized by the EU, such as EU GMP, WHO GMP, or PIC/S. Products must comply with French labeling requirements, including French language labeling and serialization mandates. Additionally, obtaining a Marketing Authorization from the ANSM is essential, ensuring that products meet the quality, safety, and efficacy standards required for sale in France.

To build a relationship with Planetpharma, Indian exporters should initiate contact through formal channels, presenting their product portfolios and demonstrating compliance with EU regulatory standards. Participating in tenders and responding to requests for proposals can provide opportunities to showcase product offerings. Developing a comprehensive regulatory filing strategy, including obtaining necessary certifications and authorizations, is crucial. Setting realistic timelines for regulatory approvals and product deliveries will facilitate a smooth partnership and integration into Planetpharma's distribution network.